西北生物治疗技术获得500万美元,最多可选择50万美元,用于资助癌症治疗研究。 Northwest Biotherapeutics secures $5M with up to $50M option to fund cancer treatment research.

西北生物治疗公司是一家开发个人化癌症治疗的生物技术公司,它从YA II PN有限公司获得了500万美元的可兑换纸币,可再购买多达5 000万美元的可兑换纸币。 Northwest Biotherapeutics, a biotech firm developing personalized cancer treatments, has secured a $5 million convertible note from YA II PN, Ltd., with an option for up to $50 million more. 这笔资金将支持公司的主要产品DCVax-L,该产品针对的是一种致命的脑癌,即血浆瘤。 This financing will support the company's lead product, DCVax-L, which targets glioblastoma, a deadly brain cancer. 该公司还就未来可能的资金需求订立了备用股权协议。 The company also has a standby equity agreement for potential future funding needs.